Williams Jones & Associates’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Williams Jones & Associates’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-32,765	Closed	-$1.34M	–	451
2017 Q3	$1.34M	Sell	32,765 -31,395	-49%	-$986K	0.03%	209
2017 Q2	$1.93M	Buy	64,160 +56,201	+706%	+$1.75M	0.05%	185
2017 Q1	$288K	Sell	7,959 -1,000	-11%	-$44.1K	0.01%	336
2016 Q4	$449K	Sell	8,959 -2,207	-20%	-$116K	0.01%	282
2016 Q3	$586K	Buy	11,166 +100	+0.9%	+$4.78K	0.02%	256
2016 Q2	$458K	Buy	11,066 +5,159	+87%	+$224K	0.01%	273
2016 Q1	$240K	Buy	+5,907	New	+$203K	0.01%	280

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Williams Jones & Associates's FPRX Position: Q4 2017 in Review

Williams Jones & Associates sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2017, closing a stake of 32,765 shares — an estimated $1.34M sold.

Williams Jones & Associates first reported a position in FPRX in Q1 2016 and held it in 7 quarters. The position peaked at $1.93M in Q2 2017. 137 funds tracked by Wall St. Rank hold FPRX as of Q4 2017.

Williams Jones & Associates reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Williams Jones & Associates sold 32,765 Five Prime Therapeutics, Inc. shares in Q4 2017, an estimated $1.34M.
Williams Jones & Associates first reported a position in Five Prime Therapeutics, Inc. in Q1 2016 and held it in 7 quarters.
Williams Jones & Associates's Five Prime Therapeutics, Inc. position peaked at $1.93M in Q2 2017.
137 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2017.

Based on Williams Jones & Associates's 13F filing for Q4 2017, filed 14 Feb 2018.